

Registered number
05439321

Caduceus Pharma Limited

Report and Accounts

31 December 2016

Caduceus Pharma Limited**Registered number:****05439321****Directors' Report**

The directors present their report and accounts for the year ended 31 December 2016.

Principal activities

The company's principal activity during the year continued to be that of the provision of nominee services.

Directors

The following persons served as directors during the year:

Michael Glanfield

Belinda Watson (resigned 5 February 2016)

Small company provisions

This report has been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime.

This report was approved by the board on 2 June 2017 and signed on its behalf.

Michael Glanfield

Director

Caduceus Pharma Limited
Profit and Loss Account
for the year ended 31 December 2016

	Notes	2016 £	2015 £
Turnover		518,146	77,274
Cost of sales		(431,039)	-
Gross profit		<u>87,107</u>	<u>77,274</u>
Administrative expenses		(11,760)	(9,511)
Other operating income		414	-
Operating profit		<u>75,761</u>	<u>67,763</u>
Profit on ordinary activities before taxation		<u>75,761</u>	<u>67,763</u>
Tax on profit on ordinary activities		(15,120)	(13,722)
Profit for the financial year		<u>60,641</u>	<u>54,041</u>

Caduceus Pharma Limited**Registered number:** 05439321**Balance Sheet****as at 31 December 2016**

	Notes	2016 £	2015 £
Current assets			
Debtors	2	38,277	28,722
Cash at bank and in hand		17,292	-
		<u>55,569</u>	<u>28,722</u>
Creditors: amounts falling due within one year	3	(41,228)	(14,522)
Net current assets		<u>14,341</u>	<u>14,200</u>
Net assets		<u>14,341</u>	<u>14,200</u>
Capital and reserves			
Called up share capital		1	1
Profit and loss account		14,340	14,199
Shareholders' funds		<u>14,341</u>	<u>14,200</u>

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.

Michael Glanfield

Director

Approved by the board on 2 June 2017

Caduceus Pharma Limited**Statement of Changes in Equity****for the year ended 31 December 2016**

	Share capital	Share premium	Re- valuation reserve	Profit and loss account	Total
	£	£	£	£	£
At 1 January 2015	1	-	-	11,158	11,159
Profit for the financial year				54,041	54,041
Dividends				(51,000)	(51,000)
At 31 December 2015	<u>1</u>	<u>-</u>	<u>-</u>	<u>14,199</u>	<u>14,200</u>
At 1 January 2016	1	-	-	14,199	14,200
Profit for the financial year				60,641	60,641
Dividends				(60,500)	(60,500)
At 31 December 2016	<u>1</u>	<u>-</u>	<u>-</u>	<u>14,340</u>	<u>14,341</u>

Caduceus Pharma Limited
Notes to the Accounts
for the year ended 31 December 2016

1 Accounting policies

Basis of preparation

The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

Debtors

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

Creditors

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

Taxation

A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.

Provisions

Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.

Foreign currency translation

Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

2 Debtors	2016	2015
	£	£
Trade debtors	33,412	28,722
VAT debtor	4,698	-
Other debtors	167	-
	<u>38,277</u>	<u>28,722</u>

3 Creditors: amounts falling due within one year	2016	2015
	£	£
Trade creditors	25,326	-
Corporation tax	15,152	13,722
Other creditors	750	800
	<u>41,228</u>	<u>14,522</u>

4 Other information

Caduceus Pharma Limited is a private company limited by shares and incorporated in England.
Its registered office is:

2 Martin House
179-181 North End Road
London
England
W14 9NL

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.